Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various... see more

Recent & Breaking News (TSXV:TLT)

Theralase(R) Extends Warrants

ACCESS Newswire September 19, 2024

Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus

ACCESS Newswire September 3, 2024

Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer

ACCESS Newswire August 28, 2024

Pharma stock Theralase paves way for in-home cancer treatment

Trevor Abes  August 21, 2024

Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug

ACCESS Newswire August 21, 2024

Theralase(R) Release's 2Q2024 Financial Statements

ACCESS Newswire August 12, 2024

Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement

ACCESS Newswire July 8, 2024

Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy

ACCESS Newswire June 20, 2024

Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically

ACCESS Newswire June 19, 2024

Theralase adds cancer immunotherapy to potential revenue streams

Trevor Abes  June 18, 2024

Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically

ACCESS Newswire June 18, 2024

Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase(R)

ACCESS Newswire June 14, 2024

Rutherrin(R) Increases Efficacy of Chemotherapy

ACCESS Newswire June 12, 2024

Theralase enhances cancer drug efficacy

Jonathon Brown June 10, 2024

Ruvidar(TM) Enhances Efficacy of Cancer Drug

ACCESS Newswire June 10, 2024

New results add billions to Theralase's addressable market

Trevor Abes  June 6, 2024

Theralase(R) Successfully Destroys Lung Cancer

ACCESS Newswire June 6, 2024

Theralase(R) Technology Effective in Virus Inactivation

ACCESS Newswire June 4, 2024

Theralase(R) Release's 1Q2024 Financial Statements

ACCESS Newswire May 30, 2024

Cancer-fighting pharma stock eyes 2027 regulatory approval

Trevor Abes  May 2, 2024